Cocrystal Pharma, Inc.

Cocrystal Pharma, Inc.

Cocrystal Pharma, Inc. is a biotechnology company publicly listed on NASDAQ under the ticker COCP, with a stated mission to discover and develop novel antiviral therapeutics. The firm's pipeline includes candidates for hepatitis C virus (HCV), norovirus, and coronaviruses, utilizing proprietary structural biology and medicinal chemistry platforms (per company filings). The company's development strategy focuses on designing small-molecule inhibitors that target viral replication enzymes. Cocrystal Pharma has advanced programs through preclinical and clinical stages, with early-phase trials reported for its HCV and norovirus candidates (per SEC filings). The geographic scope of its operations is limited, with primary activities centered in the United States. As a publicly traded firm, Cocrystal Pharma does not disclose AUM, deployment figures, or professional headcount in the context of an asset manager. The company's team size and operational scale are consistent with a small-cap biotech. No recent material operational events from the past 24 months are publicly verified beyond routine SEC disclosures. Structurally, Cocrystal Pharma operates as a research-stage biotech, not an investment vehicle or family office. Its funding comes from public equity markets and strategic partnerships, distinguishing it from firms that manage external capital or private wealth.